Dexcom (DXCM) is a biotech company that has recently been in notable news in the financial world. The firm has had various successes including the
approval of Stelo Glucose Biosensor by the FDA, and
impressive growth noted across various quarters, which suggested it as a sustainable investment for the long-term. Dexcom has managed to generate an excellent return on equity (ROE), while consistently outperforming Wall Street's earnings estimates. The
G6 CGM system of Dexcom has exponentially expanded, with the device being covered in Manitoba, as well as being combined with AID in the Netherlands. The
G7 CGM system now has connectivity with Apple watch, and its Direct-to-Watch feature will seemingly elevate the performance of the G7 system. Financial institutions, such as the Mather Group LLC and Gulf International Bank UK Ltd, have recently purchased shares of Dexcom. However, there have been some insider sell-offs and questions on debt levels that raised eyebrows. Still, growth investors are highly receiving the companyβs strong financial performance and overall bullish market sentiment.
Dexcom DXCM News Analytics from Thu, 26 Oct 2023 07:00:00 GMT to Sun, 23 Jun 2024 19:10:55 GMT -
Rating 8
- Innovation 7
- Information 7
- Rumor -3
